NeurologyLive reposted this
In a recent NeurologyLive NeuroVocies Q&A segment, Sanjay R. Patel, MD, MS, medical director of the UPMC Comprehensive Sleep Disorders Program and director of the Center for Sleep and Cardiovascular Outcomes Research, talked about a phase 3 trial assessing a pharmaceutical treatment, AD109, in sleep apnea. Read more ➡️ https://lnkd.in/eYtRsshV
It's July 1, which means a new edition of #TheAxon is hot off the press! Check out what our team has been following this past month in neurology.
In episode 14 of this Peer Exchange video series, titled "Managing Spinal Muscular Atrophy in Adult Patients," experts explored the challenges and considerations associated with patients with #SMA transitioning to independent living. 🎥 View Now: https://lnkd.in/exEZiUFZ
Take 5️⃣ minutes to stay up-to-date with our #FridayFive today! 🖐 https://lnkd.in/eJPEcNTr
In episode 8 of this Peer Exchange video series, titled "Therapeutic Options and Clinical Considerations in the Management of Spasticity," a panel of experts discuss ITB use in #spasticity treatment. 📺 Watch Now: https://lnkd.in/eX8eNvT4
🗣️🎙️In a new NeuroVoices, David Shprecher, DO, MSci, FAAN, Banner Health, talked about recent, promising advancements for diagnosing atypical Parkinsonian disorders and the questions that remain. #ATMRD24 PMD Alliance (Parkinson & Movement Disorder Alliance) 📘 Read more: https://lnkd.in/eCU6CwCu
🗣️🎙️Today we had a fantastic conversation with Anna Castagna, MD, of Fondazione Don Gnocchi, who spoke about a review of the duration of botulinum toxin efficacy in cervical dystonia clinical trials presented at #ATMRD24! Stay tuned for the interview! 🧠 🇮🇹 PMD Alliance (Parkinson & Movement Disorder Alliance) #MovementDisorders #ATMRDCongress #CervicalDystonia #PMDAlliance
Martin Tolar, MD, PhD, of Alzheon, Inc. | Preserving Future Memories, talked about the implications of early diagnosis and intervention for patients in the pre-symptomatic stages of other neurodegenerative diseases besides #AlzheimerDisease. https://lnkd.in/eA55sK4Y
New data from a multiple-ascending dose portion of the open-label, phase 1/2 HALOS study showed a resounding number of patients with #AngelmanSyndrome who had improvements in overall symptoms following treatment with investigational ION582. Ionis Pharmaceuticals, Inc. https://lnkd.in/eVM2Umuw
